Abbott Laboratories Q3 FY26: where the revenue came from and where it went
The whole income statement of Abbott Laboratories for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 4, 2026
Revenue$13.0B
+14% year over year
Gross profit$7.4B
57% margin
Operating profit$1.4B
10% margin
Net profit$0.9B
7% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 13.0 | 100% | +14% |
| Medical devices | 5.8 | 45% | +7% |
| Diagnostic products | 3.3 | 25% | +47% |
| Nutritional products | 2.3 | 17% | +5% |
| Established pharmaceutical | 1.6 | 13% | +7% |
| Cost of revenue | −5.6 | 43% | |
| Gross profit | 7.4 | 57% margin | +1pp |
| R&D | −0.9 | 7% | +0pp |
| SG&A | −4.3 | 33% | +6pp |
| Other | −0.8 | 6% | |
| Operating profit | 1.4 | 10% margin | −8pp |
| Interest & other costs | −0.1 | ||
| Tax | −0.3 | ||
| Net profit | 0.9 | 7% margin | −7pp |
2 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest